Lantheus Medical Imaging recently solidified a key component of its business strategy by acquiring the balance of the worldwide rights to ABLAVAR, an injectable MRA blood-pool imaging agent.

Prior to securing the worldwide rights to gadofoveset trisodium, which the company markets as ABLAVAR in the United States, Lantheus had the exclusive rights to it in the U.S., Canadian, and Australian markets.

This move by Lantheus will benefit both radiologists and patients, and help fuel the future growth of the company. “Our goal is to make this novel blood pool imaging agent available to patients and physicians on an expanded basis,” said Don Kiepert, president and CEO of Lantheus Medical Imaging, Inc., in a company press release. “Securing global ownership of ABLAVAR positions us well for future growth and for possible strategic opportunities and partnerships for the product in new geographic areas.”

ABLAVAR, which was launched in the United States in January, is the only contrast agent approved for MRA to evaluate aortoiliac occlusive disease in patients with known or suspected peripheral vascular disease.

(Source: Press Release)